

**Supplementary Table 1. Sensitivity analysis using the initial dataset without limitations in the follow-up period for the subgroups of users and nonusers of acid suppressants**

	Acid suppressant user (n = 5,801)			Acid suppressant nonuser (n = 9,741)		
	HR	95% CI	p value	HR	95% CI	p value
Male	1.05	0.71–1.50	0.825	0.79	0.48–1.30	0.347
Age	0.97	0.95–0.98	< 0.001	0.98	0.95–1.00	0.027
Anticoagulant	4.32	2.90–6.40	< 0.001	2.11	1.30–3.50	0.005
Aspirin <sup>a)</sup>						
4–12 weeks	0.59	0.22–1.60	0.292	0.52	0.12–2.20	0.383
≥ 12 weeks	0.23	0.10–0.54	0.001	0.33	0.09–1.20	0.098
CCI score <sup>b)</sup>						
1	3.40	1.90–6.00	< 0.001	0.98	0.49–1.90	0.950
≥ 2	4.60	2.80–7.70	< 0.001	1.91	1.10–3.30	0.018
Eupatilin use	0.62	0.36–1.10	0.102	0.93	0.37–2.30	0.870
Rebamipide use	1.45	0.99–2.10	0.057	0.88	0.44–1.80	0.716
Other MPA use	2.27	1.50–3.50	< 0.001	1.13	0.35–3.60	0.837

Acid suppressant, histamine-2 receptor antagonist or proton pump inhibitor; HR, hazard ratio; CI, confidence interval; CCI, Charlson comorbidity index; MPA, mucoprotective agent.

<sup>a)</sup>The reference category with the duration of aspirin use lasting less than 4 weeks.

<sup>b)</sup>CCI score of 0 was the reference category.